|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.KR |
First Approval Date13 Mar 2012 |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-designed, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of PK101 Compared With PK101-002 in Patients With Knee Osteoarthritis
The purpose of this study is to compare the efficacy and the safety of PK101 in patients with knee osteoarthritis.
A Randomized, Open-label, Single Dose, 2x2 Crossover Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed-dose Combination or Loose Combination of PK101 in Healthy Volunteers
The purpose of this study is to compare the safety and pharmacokinetics of PK101(fixed-dose combination of PK101-001 and PK101-002) with coadministration of the two separate drugs in healthy volunteers.
A Randomized, Open Labeled, Multiple Dose, 2-Sequence, 2-Period Cross-over Phase 1 Study to Evaluate the Drug-Drug Interaction of PK101-001 and PK101-002 in Healthy Volunteers.
To evaluate the drug-drug interaction of PK101-001 and PK101-002 in healthy volunteers.
100 Clinical Results associated with Pionex Management Group Pharm Co., Ltd.
0 Patents (Medical) associated with Pionex Management Group Pharm Co., Ltd.
100 Deals associated with Pionex Management Group Pharm Co., Ltd.
100 Translational Medicine associated with Pionex Management Group Pharm Co., Ltd.